Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Central nervous system tumor registration in the Swedish Cancer Register and Inpatient Register between 1990 and 2014

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Oncology to specialised palliative home care systematic transition: the Domus randomised trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. eHealth-mind the gap

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Purpose: High-dose chemotherapy with autologous stem cell transplantation (ASCT) is considered to be the only curative treatment option for patients with refractory or relapsed diffuse large B-cell lymphoma (DLBCL). Due to toxicity, not all patients are eligible for this treatment leading to different treatment intensities. Here, we aim to analyze the impact of treatment intensity on survival in patients previously treated with rituximab and chemotherapy, and, furthermore, to analyze the association between socioeconomic position and treatment intensity, defined as palliation, non-salvage, and salvage regimens.

Materials and methods: We identified patients with refractory or relapsed DLBCL diagnosed in 2000-2015 in the Danish National Lymphoma Registry (n=1,228). We analyzed the impact of treatment intensity on survival in patients previously treated with rituximab (n=277) using a Cox proportional hazards model. Multinomial regression analyses were performed to identify associations between socioeconomic factors and treatment intensity for the entire cohort.

Results: In the rituximab era, the 5-year overall survival (OS) was 31% for patients receiving salvage regimens (n=194), and 17% for patients receiving non-salvage regimens (n=83). In the adjusted analysis, HR was 1.88, 95% CI: 0.9-3.9 for patients receiving salvage regimens. Patients living alone were significantly less likely to receive salvage regimens, as were patients with two or more comorbidities.

Conclusion: We observed a better OS in patients treated with salvage regimens compared with non-salvage regimens; however, the adjusted analysis contradicts this. Furthermore, our results indicate that there is a chance of remission for patients not eligible for ASCT.

Original languageEnglish
JournalClinical Epidemiology
Volume11
Pages (from-to)207-216
Number of pages10
ISSN1179-1349
DOIs
Publication statusPublished - 1 Jan 2019

    Research areas

  • Chemotherapy, Education, Epidemiology, Income, Non-Hodgkin lymphoma, Socioeconomic status, Stem cell transplantation

ID: 57383209